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Targeting dendritic cells (DC) is key to driving effective immune responses. Lymphatic cannulation provides
access to the heterogeneous populations of DC draining peripheral sites in rodents and ruminants. Afferent
lymph DEC-205 CD11c SIRP DC were preferentially infected ex vivo with three vaccine viral vectors:
recombinant human replication-defective human adenovirus 5 (rhuAdV5), recombinant modified vaccinia
virus Ankara (rMVA), and recombinant fowlpox virus (rFPV), all expressing green fluorescent protein (GFP).
The rhuAdV5-infected cells remained viable, and peak GFP expression was observed 16 to 24 h posttransduc-
tion. Increasing the incubation period of DC with rhuAdV5 enhanced GFP expression. In contrast, DC infected
with rMVA-GFP or rFPV-GFP became rapidly apoptotic and GFP expression peaked at 6 h postinfection.
Delivery of foot-and-mouth disease virus (FMDV) A22 antigen to DC by rhuAdV5-FMDV-A22 ex vivo resulted
in significantly greater CD4 T cell proliferation than did delivery by rFPV-FMDV-A22. Delivery of rhuAdV5-
GFP in oil adjuvant in vivo, to enhance DC-vector contact, resulted in increased GFP expression in migrating
DC compared to that with vector alone. Similarly, CD4 T cell responses were significantly enhanced when
using rhuAdV5-FMDV-A22 in adjuvant. Therefore, the interaction between viral vectors and afferent lymph DC
ex vivo can predict the outcome of in vivo immunization and provide a means of rapidly assessing the effects of
vector modification.
Dendritic cells (DC) are potent antigen-presenting cells ca-
pable of priming naive T lymphocytes and are central to the
induction of immune responses following infection or vaccina-
tion. To present antigens to naive T cells, DC must migrate
from peripheral tissues to the closest lymph node through the
lymphatic vessels. Lymph, containing the migrating DC, can be
collected by cannulation of the afferent lymphatic vessels (22,
24). The collection of migrating DC using this method has
provided invaluable information on their phenotype and func-
tions. It has been possible to cannulate the lymphatic vessels of
a number of animal species; however, the procedure remains
technically challenging and successful only for the thoracic
duct in the rat and other lymph vessels in large animals (2, 16,
24, 44). These lymph DC are a valuable reagent to study the
interaction with potential vaccine antigens because they can be
used directly ex vivo without extensive in vitro manipulations.
The development of techniques to purify and/or mature den-
dritic cells from bone marrow, blood monocytes (MoDC), or
spleen has been an essential first step toward understanding
the physiologic function of these cells. However, these models
have limitations, especially in terms of relevance in vaccination
protocols which rely on the delivery of antigen parentally.
Another drawback for using MoDC is that these are poorly
transduced by one of the most promising recombinant vaccine
vectors, human replication-deficient recombinant adenovirus 5
(rhuAdV5) (6, 23, 39).
Afferent lymphatic DC (ALDC) represent a major popula-
tion of migrating DC (11, 12, 19, 60) with functional and
phenotypic heterogeneity. In cattle, various populations of
skin-draining ALDC have been described by their differential
expression of SIRP (CD172a), CD11a, CD26, and CD13 (4,
19, 20, 30). These populations have been shown to interact with
and stimulate T cells differently and have differential cytokine
secretion profiles (25, 30, 43, 54). An example of the hetero-
geneity of these DC is the presence of a population of migra-
tory DC characterized by the lack of expression of SIRP (18,
37, 40, 60). This subpopulation of DC is present at a higher
percentage in lymph draining from mucosal surfaces and has
been proposed to be involved in the maintenance of tolerance
(18, 31). A detailed understanding of in vivo populations of DC
at relevant anatomical sites is important to vaccine design.
In vivo targeting of dendritic cells by vaccines is an attractive
approach to improve vaccination strategies (7). However, the
study of vaccine-DC interactions ex vivo is limited by the avail-
ability of the relevant dendritic cells, that is, DC draining the
head mucosae in intranasal vaccination protocols and DC
draining the skin in subcutaneous/intradermal/intramuscular
(i.m.) vaccination approaches.
The viral vectors (rhuAdV5, recombinant modified vaccinia
virus Ankara [rMVA], and recombinant fowlpox virus [rFPV])
are being put through trials for use as vaccine vectors; there-
fore, we have tried to elucidate mechanisms to improve antigen
uptake by DC. Most vaccination strategies use the subcutane-
ous and intramuscular delivery of antigen (33, 46). Therefore,
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we have used a number of recombinant vectors expressing
green fluorescent protein (GFP) to identify the dendritic cell
subsets which are naturally targeted by these vectors.
In this study, we use dendritic cells collected from calves
which had their cervical lymph nodes surgically removed and
the draining lymphatic vessels cannulated for the collection of
cells draining the skin, providing a source of cells relevant in
subcutaneous/intramuscular vaccination protocols. We ana-
lyzed the interaction of these ALDC with human adenovirus 5
(rhuAdV5), recombinant modified vaccinia virus Ankara
(rMVA), and recombinant fowlpox virus (rFPV) and per-
formed ex vivo functional studies. We show that the results of
our ex vivo studies, with the most promising vaccine candidate
being rhuAdV5, could be used to predict the outcome of in
vivo vaccination studies.
MATERIALS AND METHODS
Pseudoafferent lymphatic cannulation. Outbred conventionally reared
6-month-old Friesian Holstein calves (Bos taurus) from the Institute for Animal
Health (IAH) herd were used for these studies. Cannulations were performed
essentially as previously described (24). Lymph was collected into sterile plastic
bottles containing heparin (10 U/ml), penicillin, and streptomycin. Either the
lymph collected was used fresh (for uptake studies), or it was centrifuged (300 
g, 8 min) and resuspended in fetal calf serum (FCS)-10% dimethyl sulfoxide
(DMSO) and the cells were stored in liquid nitrogen prior to use. For uptake
studies, the mononuclear cells were isolated from the afferent lymph by density
gradient centrifugation over Histopaque (1083; Sigma). Animal experiments
were approved by the IAH ethics committee according to national United King-
dom guidelines.
MAb and flow cytometry. Fluorochrome-labeled mouse anti-bovine monoclo-
nal antibodies (MAb) used in this study have been described in detail previously
(4, 28–30, 50). These were CC98-allophycocyanin (APC) (anti-DEC-205), CC21-
phycoerythrin (PE) (anti-CD21), CC14-PE (anti-CD1b), CC149-peridinin chlo-
rophyll protein (PerCP)/Cy5.5 (anti-SIRP), ILA-16-Alexa Fluor 680/PE (anti-
CD11c), ILA-21-PE (anti-major histocompatibility complex class II [anti-MHC
II]), ILA-156-PE (anti-CD40), N32/52-3-PE (anti-CD80), ILA-159-PE (anti-
CD86), CC30-APC/Cy5.5 (anti-CD4), CC63-APC/Cy7 (anti-CD8), ILA-111-
Alexa Fluor 610/PE (anti-CD25), and CC302-PE (anti-gamma interferon [anti-
IFN-]). Expression of mannose receptor (MR) was detected with a commercial
MAb (clone CD206) from Beckman Coulter. Control MAb were isotype- and
concentration-matched anti-avian MAb (24, 59). The cells were analyzed using
an LSRFortessa cell analyzer (Becton Dickinson), and staining was assessed
using FCS Express (DeNovo Software). Afferent lymph DC were distinguished
from other cells on the basis of their high forward scatter (FSC) and high-
intensity expression of DEC-205 (19, 24).
Cell sorting. Cells were sorted into the various dendritic cell populations using
a FACSAria cell sorter (Becton Dickinson), and purities were confirmed by flow
cytometry using FACSDiva v5 (Becton Dickinson). T cell subsets were magnet-
ically separated using magnetically activated cell sorting (MACS) technology
(Miltenyi Biotech, Germany) according to the manufacturer’s instructions. Typ-
ically, the purity of the resulting dendritic and T cell subsets was over 97% as
determined by flow cytometry.
Recombinant vectors. The generation of recombinant MVA and FPV express-
ing GFP has been described previously (3, 13). Replication-deficient human
recombinant adenovirus 5 (rhuAdV5) vectors expressing either green fluorescent
protein (GFP) or foot-and-mouth disease virus (FMDV) antigen were produced
by the Jenner Institute Viral Vector Core Facility, University of Oxford, United
Kingdom, using the ViraPower Adenoviral Expression System (Invitrogen) ac-
cording to the manufacturer’s instructions. Briefly, GFP or FMDV A22 Iraq
P1-2A-3B-3C was cloned into pENTR4 followed by in vitro recombination using
LR clonase into the E1- and E3-deleted pAd/PL-DEST AdHu5 genome vector.
Prior to transfection, the plasmid was linearized using PacI restriction enzyme to
expose the inverted terminal repeats.
293TREx cells (Invitrogen) were transfected with linearized plasmid DNA
using Lipofectamine 2000 (Invitrogen). The cells were cultured in complete
medium (10% fetal bovine serum [FBS], Dulbecco modified Eagle medium
[DMEM], 5 g/ml blasticidin) until cytopathic effects (CPE) were observed by
microscopy. The cells were harvested and lysed by freeze-thawing. The cell lysate
was used to infect a bulk preparation of TREx cells, and the culture was har-
vested when CPE was evident throughout the cell monolayer. The resultant
recombinant adenovirus was purified using both discontinuous and isopycnic
CsCl gradient ultracentrifugation. The purified virus finally was buffer exchanged
into storage buffer (10 mM Tris, 7.5% [wt/vol] sucrose, pH 7.8) and stored at
80°C until required. Infectious units (IU) were calculated using the Adeno-X
Rapid Titer kit (Clontech) according to the manufacturer’s instructions.
Foot-and-mouth disease virus antigens. Killed FMDV antigen was obtained
from Merial (A22 Iraq 24/64) (Merial Animal Health Ltd., United Kingdom).
BHK cell lysate was used as a negative control for FMDV antigen.
Infection of afferent lymph cells. Afferent lymph cells were cultured in tissue
culture medium (TCM; Iscove’s modified Dulbecco’s medium [IMDM] contain-
ing 10% FCS [Autogen Bioclear, United Kingdom], 105 M 2--mercaptoeth-
anol [Sigma-Aldrich, Poole, United Kingdom]) with the recombinant viruses at
optimal multiplicities of infection (MOI); these were determined by titrating the
recombinant viruses on ALDC (MOI of 1, 10, 100, and 1,000), and the optimal
ratios were found to be as follows: rhuAdV5, 100 infectious units/cell; rMVA and
rFPV, 1 PFU/cell. The frequency of cells expressing GFP was less than 1%, and
approximately 8% were apoptotic, when incubated with rhuAdV5-GFP at MOI
of 1 and 10; similar values were detected in mock-infected cultures. When cells
were incubated with rhuAdV5 at an MOI of 100 or above, approximately 34% of
cells expressed GFP and approximately 9% of cells were apoptotic. In rMVA-
and rFPV-infected cultures, no effect on cell viability was seen at an MOI of 0.1
but approximately 55% of cells were apoptotic/dead using MOI of 1 and 10 after
3 h postinfection. No GFP expression was detected in cells infected at an MOI
of 0.1, but approximately 20% of cells were GFP positive at an MOI of 1.
Subsequently, studies were performed by incubating cells at 37°C with rhuAdV5
at an MOI of 100 for 16 to 24 h and with rMVA and rFPV at an MOI of 1 for
6 h. Cells were extensively washed following infection and fixed with 1% para-
formaldehyde for 30 min prior to flow cytometric analysis.
Recombinant virus uptake by afferent lymph veiled cells in vivo. For in vivo
assessment of uptake, 5  109 IU of rhuAdV5-GFP (46) in 0.5 ml phosphate-
buffered saline (PBS) were emulsified with 0.5 ml Montanide ISA-206V (Seppic,
France) and injected either intramuscularly or subcutaneously in the area drain-
ing to the pseudoafferent lymphatic vessel (24). Lymph was collected at 4-hourly
intervals up to 12 h and then at 48 h and 72 h. The lymph cells were cultured for
12 h at 37°C in the presence of penicillin-streptomycin-gentamicin (1 g/ml), to
allow the expression of GFP. Then, cells were fixed for 30 min with 1% para-
formaldehyde and subjected to multicolor flow cytometric analysis.
Apoptosis assays. Cells were resuspended to 1  106 cells per 0.1 ml in mixed
prepared reagents of the TACS annexin apoptosis kit (R&D Systems, Minne-
apolis, MN) according to the manufacturer’s instructions and analyzed by flow
cytometry.
Antigen presentation and T cell responses. Populations of dendritic cells were
purified by fluorescence-activated cell sorting (FACS), washed five times with
phosphate-buffered saline (PBS), and incubated with recombinant vectors or
TCM for 60 min at 37°C in a 96-well U-bottomed plate (Costar). A 60-min
incubation period, before the addition of T cells, was used to allow comparison
between vectors, prior to extensive apoptosis in some cultures. The cells were
washed twice with PBS, resuspended in TCM, and mixed with autologous
MACS-sorted CD4 T and CD8 T cells from conventional FMDV-vaccinated
animals, at 3 weeks postvaccination, at a ratio of 1 DC to 10 T cells in a final
volume of 200 l (38). For detection of IFN- expression by enzyme-linked
immunosorbent spot (ELISpot) assay, the cells were transferred to a nitrocellu-
lose-backed 96-well MultiScreen hemagglutinin (HA) plate (Millipore, Bedford,
MA), which had been coated with 100 l of 8 g/ml anti-bovine IFN- MAb
CC330. The cells were incubated for 24 h at 37°C, and the assay continued as
previously described (26). Secretion of IFN- and interleukin-10 (IL-10) was
detected by enzyme-linked immunosorbent assay (ELISA) as previously de-
scribed (10, 25, 34). For T cell proliferation by [3H]thymidine incorporation, DC
or gamma-irradiated peripheral blood mononuclear cells (PBMC) were mixed
with autologous CD4 T cells in a 96-well U-bottomed plate (Costar) in the
presence of antigens. The cells were incubated at 37°C for 5 days. Then, the cells
were pulsed with 0.5 Ci of [methyl-3H]thymidine (Perkin-Elmer) and the assay
continued as previously described (9). In some assays, proliferation was assessed
by labeling cells with carboxyfluorescein diacetate succinimidyl ester (CFDA-
SE); cells were resuspended to 1  107 cells per ml in warm PBS and mixed with
an equal volume of CFDA-SE (Invitrogen; final concentration, 5 M). Following
15 min of incubation at 37°C, the cells were washed twice and resuspended to 5
106 cells per ml in warm TCM. The cells were incubated at 37°C for 30 min,
washed once, and then cultured overnight in TCM at 37°C. Cells were washed
and analyzed by flow cytometry. The results are shown as percent proliferation
determined as the percent CFSELOW cells.
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Vaccination protocols. To assess whether expression of antigen by DC trans-
duced by rhuAdV5 would improve vaccine immunogenicity in vivo, groups of
outbred weight- and age-matched conventionally reared Friesian Holstein cattle
(n  3) were vaccinated intramuscularly with 1 ml of rhuAdV5-FMDV-A22 (5 
109 IU/animal) in the presence or absence of water-in-oil-in-water adjuvant
(Montanide ISA-206V; Seppic, France) or conventional inactivated FMDV vac-
cine (O1 Manisa/A22 Iraq; Intervet, United Kingdom) or PBS.
Statistical analyses. Data are presented as means 	 standard deviations, and
groups were compared using one-way analysis of variance (ANOVA) and pair-
wise comparison using GraphPad Prism v5. Data for in vivo migration of DC
following inoculation of rhuAdV5-GFP were analyzed using linear mixed models
including time and treatment and an interaction between these factors as fixed
effects and animal as a random effect. This interaction was significant (as judged
by the Akaike information criterion) for all analyses. Results for “adjuvant only”
were excluded from all analyses except percent DEC-205, because the observa-
tions for this factor were all zero.
RESULTS
Dendritic cells draining the skin are effectively targeted by
recombinant vectors. The subsets of dendritic cells that drain
the skin of cattle (27) and an improved method for collecting
such cells have been described previously (24). Afferent lymph
cells draining the skin were isolated and cultured in vitro with
either rhuAdV5, rMVA, or rFPV. In initial experiments, vi-
ruses expressing GFP were utilized for ease of detection by
flow cytometry. A significant increase of GFP expression was
observed as early as 3 h postinfection with rMVA and rFPV
(P  0.0003) but no earlier than 12 h following transduction
with rhuAdV5 (P  
0.0001) (Fig. 1A). Peak GFP expression
was observed at 6 h with both rMVA and rFPV, in cells re-
maining viable, after which time GFP expression remained
stable (rMVA) or decreased significantly (rFPV). Expression
of GFP by ALDC transduced with rhuAdV5 continued to
increase up to 24 h. Virus replication was not productive in
ALDC infected with rMVA or rFPV as measured by plaque
assay and immunofluorescence to detect virus capsids using
monospecific sera (data not shown).
Dendritic cells infected with all three recombinants ex-
pressed GFP, with rhuAdV5 transducing a higher percentage
of FSChigh DEC-205 cells and fluorescence intensity being
higher than that with both rMVA and rFPV (Table 1). Inter-
estingly, total numbers of FSChigh DEC-205 cells in the cul-
tures infected with rMVA and rFPV were reduced (Fig. 1B
and Table 1). To identify whether this was due to virus-induced
cytotoxicity and subsequent reduction in GFP expression, we
measured cell death using propidium iodide and annexin V-
fluorescein isothiocyanate (FITC) at various time points
postinfection. Cells transduced with rhuAdV5 remained viable
throughout the infection period. In contrast, DC infected with
rMVA and rFPV became apoptotic (Fig. 1C).
In contrast to ALDC, bovine monocyte-derived DC
(MoDC) and bone marrow-derived DC matured in the pres-
ence of granulocyte-macrophage colony-stimulating factor
(GM-CSF) and IL-4 were not infected by rhuAdV5, and the
quantity and kinetics of GFP expression in rMVA- and rFPV-
infected MoDC and bone marrow-derived DC were similar to
those of ALDC (data not shown).
Virus vectors infect various subsets of DC. Dendritic cells
draining the skin and muscle were defined as FSChigh DEC-
205 (Fig. 1D); all of these DC were CD11c CD8 (Fig. 1E).
Within the DEC-205 DC, there were subpopulations of DC
which differentially expressed CD1b, CD21, and SIRP. To
identify virus vector tropism in subsets of DC, we added GFP-
expressing viruses to freshly isolated pseudoafferent lymph
cells and utilized multicolor flow cytometry to identify those
DC which expressed GFP. All three viral vectors preferentially
infected DEC-205 SIRP dendritic cells (Fig. 1F), with sig-
nificant GFP expression being observed in SIRP cells
(40.92, 31.57, and 26.02% of GFP expression for rhuAdV5,
rMVA, and rFPV, respectively) but not SIRP cells. Within
this subpopulation, rhuAdV5 preferentially transduced
CD1b DC; rMVA infected CD1b and rFPV infected
CD1b/ dendritic cells (Fig. 1G). There was evidence for
downregulation of CD1b by rFPV. CD1b DC were purified
and then infected with rFPV; after 6 h in culture, viable
CD1b GFP-positive cells were detected (data not shown).
rhuAdV5 and rMVA infected both CD21 and CD21 cells;
in contrast, GFP expression in rFPV-infected DC was mostly
detected in CD21 cells (Fig. 1H).
To further assess whether vector tropism was limited to the
SIRP DC, we purified FSChigh DEC-205 SIRP and
SIRP DC and cultured these with the recombinant viral
vectors expressing GFP. Interestingly, SIRP DC, which
were not targeted by recombinant vectors in mixed culture
(Fig. 1F), showed GFP expression similar to that observed in
SIRP DC (Fig. 2A) when purified cell cultures were uti-
lized. Significant differences between the percentages of
SIRP and SIRP DC expressing GFP were observed only
for rMVA (P 0.03). The enhanced expression of GFP (mean
fluorescence intensity [MFI]) in total DC populations (Table
1) infected with rhuAdV5 compared to those infected with
rMVA and rFPV was also observed with purified SIRP and
SIRP DC populations (P  0.001; Fig. 2B).
rMVA and rFPV regulate costimulatory molecules. Den-
dritic cells draining the skin and muscle express the costimu-
latory molecules MHC II, CD40, CD80, and CD86 (24). Cul-
turing cells in tissue culture medium for 6 h without the
addition of cytokines, or viral vectors, increased the expression
of CD40 and CD86, but not of CD80 and MHC II, on SIRP
DC (Table 2); similar results were seen in gated SIRP DC
populations (data not shown). To identify whether the recom-
binant vectors had any effect on the expression of costimula-
tory molecules, freshly isolated DC were infected with recom-
binant viruses and analysis was performed on gated SIRP
DC. Transduction with rhuAdV5 did not have a significant
effect on the expression of any of the costimulatory molecules
measured 16 h posttransduction compared to cells cultured for
the same time period in medium alone, although expression of
each molecule was significantly increased compared to the
control (P 
 0.005). In contrast, at the time point where peak
GFP expression was observed in DC infected with rMVA (6 h),
there was significant downregulation of CD40, CD86, and
MHC II (Table 2) but not of CD80 compared to DC cultured
in medium alone. Recombinant fowlpox virus-infected DC
showed downregulation of CD40 only; CD80, CD86, and
MHC II were not affected at 6 h (Table 2). No significant
changes in costimulatory molecule expression were observed in
the gated SIRP DC populations after incubation with the
recombinant vectors compared to culture in medium alone.
SIRP DC efficiently present antigen to T lymphocyte sub-
sets. We investigated the ability of DC transduced with
rhuAdV5 or infected with rFPV to present foot-and-mouth
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FIG. 1. Dendritic cells infected with the recombinant viruses expressed GFP. (A) Afferent lymph cells were transduced with rhuAdV5, rMVA,
or rFPV and analyzed by flow cytometry. Dendritic cells were gated as FSChigh DEC-205 cells, and the percentage of GFP-expressing cells was
calculated at the indicated time points (n  4). NoV, no virus. (B) Dot plots of afferent lymph cells expressing DEC-205 following infection with
recombinant viruses; green events represent GFP cells. (C) Dendritic cells were gated as FSChigh DEC-205 cells, and dot plots show the
percentages of apoptotic/dead cells measured using propidium iodide (PI) and annexin V. (D) Dendritic cells draining the skin were gated as
FSChigh DEC-205. (E) Expression of CD11c and CD8 was assessed. (F) Vector-encoded GFP expression was analyzed in subsets of FSChigh
DEC-205 DC expressing SIRP. (G) Expression of FSChigh DEC-205 SIRP/ CD1b/. (H) Expression of FSChigh DEC-205 SIRP
CD21/. (F to H) Dendritic cells were infected with rhuAdV5-GFP for 16 h (n  5) or infected with rMVA or rFPV for 6 h (n  5). Error bars
indicate standard deviations.
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disease virus (FMDV) antigens to T cells in vitro. Recombinant
MVA was not tested since the expression of the FMDV anti-
gen cassette has not been possible in vaccinia virus. Initially,
various ratios of DC to T cells were tested and the optimal
ratio to induce T cell activation was found to be 1:100 (data not
shown). FSChigh, DEC-205, and SIRP DC were trans-
duced with rhuAdV5-FMDV-A22 or infected with rFPV-
FMDV and cultured with purified autologous CD4 T cells
isolated from the cattle at 3 weeks postvaccination. DC trans-
duced with rhuAdV5-FMDV-A22 induced antigen-specific T
cell proliferation more efficiently than did DC infected with
rFPV-FMDV (P  0.0003) (Fig. 3A). Both viruses induced
significantly lower proliferation than did purified protein anti-
gen (P  0.061 and P  0.003 for rhuAdV5 and rFPV, respec-
tively). To identify which DC subset was responsible for anti-
gen presentation following delivery of antigen using
recombinant viruses, FACS-purified populations of DC were
tested for their ability to activate purified CD4 and CD8 T
cells from FMDV-vaccinated cattle. Only SIRP DC were
able to induce significant FMDV-specific IFN- expression by
both CD4 and CD8 T cells (P  0.001 compared to
SIRP) (Fig. 3B and 3C). rhuAdV5-FMDV induced a higher
expression of IFN- than did purified protein antigen as a
positive control for CD4 T cells and CD8 T cells, respec-
tively (P  0.0003 and P  0.0471, respectively). rFPV-FMDV
induced more IFN- than did the FMDV antigen on CD4 T
cells only (P  0.002).
Interestingly, SIRP DC subsets were infected in purified
cultures, but they were unable to present antigen to CD4 and
CD8 T cells (Fig. 3B and 3C, respectively).
Skin-draining DEC-205 dendritic cells are efficiently
transduced by recombinant adenovirus in vivo. Subsequent to
demonstrating the transduction capacity of rhuAdV5 on affer-
ent lymph DC and their capacity to effectively present antigen
in vitro, we investigated the ability of rhuAdV5 delivered either
intramuscularly or subcutaneously to infect skin-draining DC
in vivo. Cattle were inoculated subcutaneously above the site of
cannulation with rhuAdV5-GFP (5  109 IU/animal) in the
presence or absence of a water-in-oil-in-water adjuvant (Mon-
tanide ISA-206V). Draining DC were collected at 4-h intervals,
and the phenotype of the draining DC and GFP expression was
measured by flow cytometry. There was no significant change
over time in the frequency of migrating DC (FSChigh DEC-
205) in the groups of animals inoculated with rhuAdV5-GFP
without adjuvant or those inoculated with adjuvant alone.
However, there was a significant rise (P 
 0.0003) during the
first 15 h in the frequency of migrating DC in the groups of
animals vaccinated with rhuAdV5-GFP in the presence of ad-
juvant (Fig. 4A). We analyzed the phenotypic composition of
subsets of DC following inoculation. The frequencies of mi-
gration of GFP-positive FSChigh DEC-205, FSChigh DEC-
205 SIRP, and FSChigh DEC-205 SIRP CD1b DC
(Fig. 4B, C, and D) were significantly (P  0.0348, P  0.0092,
and P  0.0395, respectively) increased following subcutane-
ous inoculation of rhuAdV5 in the presence of adjuvant. GFP
expression in DC was evident as early as 5 h postinoculation
and detectable by flow cytometry for up to 15 h in the FSChigh
DEC-205 subset (Fig. 4B), the FSChigh DEC-205 SIRP
subset (Fig. 4C), and the FSChigh DEC-205 SIRP CD1b
subset (Fig. 4D). Similar GFP expression profiles were ob-
served in animals inoculated intramuscularly with rhuAdV5-
GFP in the presence of water-in-oil-in-water adjuvant (data
not shown).
Induction of antigen-specific responses in vivo with
rhuAdV5-FMDV-A22. Further to demonstrate that rhuAdV5 is
capable of transducing DC both in vitro and in vivo and that
this enhances antigen presentation in vitro, we investigated the
possibility of enhancing the immune response to FMDV using
TABLE 1. Infection of dendritic cells in vitro by
recombinant vectorsa
DC No virus rhuAdV5 rMVA rFPV
% expressing
GFP
0.34 	 0.01 34.09	 8.1 29.98	 9.4 24	 8.7
MFI (GFP) 109 	 11 570	 33 172	 22 257	 31
No. expressing
GFP
41 	 5 3677 	 98 683	 55 550	 15
Total no. 11,848 	 121 10,788	 155 2,278	 111 2,252	 78
a Dendritic cells draining the skin were gated as FSChigh DEC-205. Dendritic
cells were infected with rhuAdV5-GFP for 16 h (n  5) or infected with rMVA
or rFPV for 6 h (n  5). Standard deviations are shown.
FIG. 2. Purified subsets can be more readily infected than mixed populations. FACS-sorted DC subsets were transduced for 16 h with rhuAdV5
(n  5) or infected for 6 h with rMVA and rFPV (n  10). GFP expression was measured by flow cytometry. (A) Frequency of GFP-expressing
DC subsets. (B) Mean fluorescence intensity (MFI) of GFP expression. Error bars indicate standard deviations.
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rhuAdV5 plus adjuvant. Groups of calves (n  3) were inoc-
ulated intramuscularly (i.m.) with rhuAdV5-FMDV-A22 at 5
109 IU/animal, the same dose used in previous vaccination
studies (46), with or without adjuvant, PBS prepared in the
same adjuvant, or a commercially available inactivated FMDV
vaccine. Both groups of cattle immunized with rhuAdV5-
FMDV-A22 developed FMDV-specific IgG antibody responses
comparable to but not statistically different from those of the
animals vaccinated with conventional vaccine; the negative-
control group did not seroconvert (data not shown).
CD4 and CD8 FMDV-specific proliferation was mea-
sured by CFDA-SE dilution; neither group immunized with
rhuAdV5-FMDV-A22 showed a significantly increased T cell
proliferative response (Fig. 5A and B).
FMDV-specific cellular responses were also measured by
ELISpot assay and intracellular cytokine staining. MACS-
sorted CD4 T cells from animals vaccinated with recombi-
nant vector in adjuvant showed significantly higher IFN- re-
lease to FMDV antigen than did those animals vaccinated with
recombinant vector in the absence of adjuvant or animals vac-
cinated with inactivated FMDV (P  0.0002) (Fig. 5C).
We also analyzed the phenotype of T cell responses follow-
ing vaccination by flow cytometry. The frequency of CD4
IFN- and CD4 tumor necrosis factor alpha-positive (TNF-
) (Fig. 5D and E, respectively) T cells was increased in the
group immunized with rhuAdV5-FMDV-A22 formulated in
adjuvant compared to the group immunized with rhuAdV5-
FMDV-A22 alone. There was no significant difference in the
frequencies of CD4 IL-4 T cells in the two groups immu-
nized with rhuAdV5-FMDV-A22 (Fig. 5F). There was no sig-
nificant difference in the frequencies of CD8 T cells express-
ing IFN- and TNF- among the vaccinated groups (data not
shown).
DISCUSSION
The main role of dendritic cells is the presentation of anti-
gen to T cells, in particular, priming of naive T cells within the
lymph node (47, 55). Most systems used to investigate DC-T
cell interactions rely on the isolation of monocytes or macro-
phages from blood or tissues (such as spleen or bone marrow)
(49, 53), followed by maturation with IL-4 and GM-CSF, or the
harvesting of tissues followed by isolation of resident DC.
Published results suggest that peripheral dendritic cells in the
epithelia take up antigen by pinocytosis, macropinocytosis, or
receptor-mediated endocytosis (5, 30, 42). Peripheral dendritic
cells then migrate via the afferent lymphatic ducts to the drain-
ing lymph nodes, losing their ability to uptake antigen but
becoming very potent antigen-presenting cells. This model is
challenged by the identification of dendritic cells from afferent
lymph, the afferent lymph veiled cells (42), which migrate from
peripheral tissues which are able to process antigen and are
potent stimulators of resting and naive T cells.
We have previously shown that dendritic cells draining the
FIG. 3. Dendritic cells draining the skin effectively present foot-and-mouth disease virus antigens. DC were cultured with recombinant vectors
encoding FMDV antigens or loaded with purified FMDV antigen (1 g) and cultured with autologous MACS-sorted CD4 T cells from
FMDV-vaccinated cattle (n  4). (A) FMDV-specific responses were measured by thymidine incorporation. (B and C) Differential antigen
presentation by SIRP (filled bars) or SIRP (gray bars) cells to CD4 (B) and CD8 (C) T cells. Asterisks indicate P values of
0.001. Results
are shown as median spot-forming units (SFU) per 106 cells. Error bars indicate standard deviations.
TABLE 2. Expression of costimulatory molecules CD40, CD80, CD86, and MHC II in FSChigh DEC-205 SIRP cells
following infection with recombinant viruses
Costimulatory
protein
% expression 	 SD at time postinfectiona:
16 h 6 h 0 h,
noninfected
cells
rhuAdV5-infected
cells
Noninfected
cells
rMVA-infected
cells
rFPV-infected
cells
Noninfected
cells
CD40 94.75	 1.64* 93.13	 3.3* 42.69	 2.3*† 36.8	 0.2*† 87.0	 5.4* 62.0	 5.0
CD80 79.54	 14.60 84.89	 0.0 94.3	 1.4 94.2 	 1.6 89.6 	 8.3 90.4	 3.3
CD86 95.06	 4.6* 89.5 	 0.1* 62.9	 1.8*† 81.0	 5.7* 88.8	 0.1* 42.67	 4.5
MHC II 91.1	 6.3 90.38	 1.2 63.5	 18.3† 87.3	 5.8 92.9 	 3.5 86.63	 4.7
a Asterisks indicate P 
 0.005 compared to noninfected cells at 0 h. Daggers indicate P 
 0.005 compared to noninfected cells after culture.
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skin of cattle which were collected by cannulation of pseudo-
afferent lymphatic vessels (24) express high levels of DEC-205
(CD205). DEC-205 is an endocytic receptor which mediates
uptake of antigens on dendritic cells. DEC-205 is currently the
only receptor which has been visualized on most DC in the T
cell area of secondary lymphoid tissues, which are the sites for
the generation of immunity and tolerance in mouse models
and humans (7, 21). Targeting of DEC-205-expressing DC by
either chimeric antigen-antibody complexes or recombinant
vectors has been proposed to be an effective approach to im-
prove immune responses (7, 57).
DC draining the skin were found to be FSChigh DEC-205
CD11c CD8 cells. Within this population, two major sub-
populations can be identified, those cells expressing SIRP
and those not expressing SIRP (30, 42). Although both pop-
ulations express high levels of costimulatory molecules (CD40,
CD80, and CD86) and MHC II, it has previously been shown
that only the SIRP-expressing cells present antigen effi-
ciently (30).
We now show that in mixed cultures, only the DC expressing
SIRP are efficiently targeted by the recombinant replica-
tion-deficient viral vectors human adenovirus 5 (rhuAdV5),
modified vaccinia virus Ankara (rMVA), and fowlpox virus
(rFPV), which all have potential use as safe vaccine vectors
(14, 35, 41, 56, 61). Surprisingly, engagement of Toll-like re-
ceptor (TLR) ligands did not increase vector uptake, the quan-
tity of antigen expression, or upregulation of cell surface mark-
ers (data not shown). Interestingly, physical separation of
SIRP cells allowed for efficient infection by the recombinant
viruses; however, these cells did not efficiently present antigen
to T cells, supporting previous data (30, 37). This observation
is more interesting given that SIRP cells represent up
to 30% of ALDC and express high levels of costimulatory
molecules. The DC expressing SIRP are represented by a
heterogeneous mix of DC all capable of presenting antigen.
Recombinant vectors differentially target these various sub-
populations so that rhuAdV5 targets CD1b CD21 DC,
rMVA targets CD1b and both CD21 and CD21 DC, and
rFPV targets CD1b and both CD21 and CD21 DC. The
biological significance of this differential targeting of DC is still
unknown.
Interestingly, during our pilot experiments we found that
bovine monocyte-derived DC grown in the presence of GM-
CSF and IL-4 were poorly transduced by the rhuAdV5 vector,
supporting data described for the human system (6). It was also
interesting to observe the frequency of vector-induced cytotox-
icity following infection of ALDC with rMVA and rFPV even
at low frequencies (MOI  1). Although there are reports of
rMVA-induced cytotoxicity in monocyte-derived and bone
marrow-derived dendritic murine DC (36), to our knowledge
FIG. 4. rhuAdV5-GFP uptake by DC subsets draining the skin following subcutaneous inoculation in the presence of adjuvant. Cannulated
calves (n  3/group) were inoculated with rhuAdV5-GFP subcutaneously in the presence (closed symbols) or absence (open diamonds) of
adjuvant. Control cattle were inoculated with adjuvant only (open squares). Cells draining the skin were collected at 4-h intervals up to 12 h and
then at 24, 48, and 72 h; GFP expression and surface cell markers were measured by flow cytometry. (A) The frequency of DC in the group of
animals vaccinated with rhuAdV5-GFP in the presence of adjuvant was increased (P 
 0.0003) during the first 15 h postinoculation. (B to D) The
frequencies of GFP-positive cells were significantly increased in the FSChigh DEC-205 cells (P  0.0348) (B), FSChigh DEC-205 SIRP cells
(P  0.0092) (C), and the FSChigh DEC-205 SIRP CD1b cells (D) in the animals treated with rhuAdV5-GFP plus adjuvant. Error bars
indicate standard deviations.
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this is the first report of rMVA- and rFPV-induced cytotoxicity
of dendritic cells draining tissues which would normally be
targeted in vaccine delivery protocols. It is important to point
out that apoptosis was observed 12 to 24 h postinfection in
human MoDC and macrophages infected with MVA (62),
whereas in our system we observed cell death as soon as 3 h
postinfection. Apoptosis induction by live vector vaccines may
have important effects on the resulting immune response.
While rapid apoptosis may limit antigen expression and thus
adversely impact on specific immunity to vector-encoded anti-
gens, apoptotic responses may also be desirable for antigen
uptake and presentation through the alternative class I pre-
sentation pathway (antigen cross-priming) (17, 48, 51).
We demonstrated that rhuAdV5 was the most efficient of
the three vectors studied at stimulating T cell responses in
vitro. MVA- and FPV-infected dendritic cells did not secrete
inhibitory cytokines as measured by ELISA (data not shown),
and therefore the reason for differential capacity to present
vector-encoded antigens is still unknown. We also confirmed
previous studies that DEC-205 SIRP DC were the most
efficient stimulators of T cell responses in vitro. Subsequently,
we performed in vivo experiments in which rhuAdV5-GFP was
administrered to cannulated calves. We observed that the ma-
jority of GFP-expressing cells were FSChigh DEC-205,
FSChigh DEC-205 SIRP, and FSChigh DEC-205 SIRP
CD1b. GFP expression in FSChigh DEC-205 SIRP cells
FIG. 5. T cell responses to FMDV following vaccination. Groups of animals (n  3) were vaccinated with PBS, inactivated FMDV, rhuAdV5-
FMD, or rhuAdV5-FMDV-A22 with adjuvant. (A) CD4
 T cell CFDA-SE proliferation at 3 weeks postvaccination. (B) CD8 T cell CFDA-SE
proliferation at 3 weeks postvaccination. (C) FMDV-specific IFN- from MACS-sorted CD4 T cells was measured by ELISpot assay 6 weeks
postvaccination. Results are shown as median spot-forming units (SFU) per 106 cells. (D to F) FMDV-specific intracellular cytokine expression
ex vivo on CD4 T cells gated at 6 weeks postvaccination. (D) Percent IFN- on CD4 T cells. (E) Percent TNF- on CD4 T cells. (F) Percent
IL-4 on CD4 T cells. N.S., no significant difference. Error bars indicate standard deviations.
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was not statistically different from background fluorescence
(data not shown), indicating that rhuAdV5 is not capable of
transducing this subset of dendritic cells. Also, there was an
increase in the total number of DC in the pseudoafferent
lymph soon after vaccination with adenovirus and adjuvant.
Overall, there were higher numbers of GFP-expressing cells in
calves vaccinated with rhuAdV5-GFP emulsified with adju-
vant, suggesting that the adjuvant increases migration of DC to
the site of inoculation and thus increases antigen uptake and
subsequent migration of antigen-bearing DC to the lymph
node (8, 15, 52), This supports the notion that lymph-migrat-
ing, tissue-derived dendritic cells are constituents within
steady-state lymph nodes and that their frequency increases
after introduction of an inflammatory stimulus (32).
In light of the results of our in vitro and in vivo studies, we
immunized animals with rhuAdV5-expressing FMDV antigens
in the presence or absence of a water-in-oil-in-water adjuvant.
Interestingly, the use of adjuvant had a significant effect on the
frequency of CD4 IFN- and CD4 TNF- T cells. Sim-
ilarly, the frequency of CD4 T cells secreting antigen-specific
IFN- was increased in animals vaccinated with rAdV5-FMDV
in the presence of adjuvant. Our studies demonstrate that the
quantity of antigen delivered by viral vectors to DC can be
enhanced by using oil adjuvant formulations, with a subse-
quent enhancement of specific T cell responses (1, 45, 52, 58).
Furthermore, ex vivo studies of the interaction between viral
vector constructs with DC from afferent lymph could be used
to predict the outcome of vaccination studies with novel vac-
cine formulations.
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